X-tremeGENE siRNA Transfection Reagent
X-tremeGENE siRNA Transfection Reagent efficiently delivers short interfering RNA (siRNA) into many commonly used cell types including HeLa, NIH 3T3, HEK-293, CHO-K1, and COS-7, and several hard-to-transfect cell lines such as HT29, a human adenocarcinoma cell line. When used for cotransfection-based gene knockdown, X-tremeGENE siRNA Transfection Reagent enables significant protein expression and effective knockdown levels due…
X-tremeGENE siRNA Transfection Reagent efficiently delivers short interfering RNA (siRNA) into many commonly used cell types including HeLa, NIH 3T3, HEK-293, CHO-K1, and COS-7, and several hard-to-transfect cell lines such as HT29, a human adenocarcinoma cell line.
When used for cotransfection-based gene knockdown, X-tremeGENE siRNA Transfection Reagent enables significant protein expression and effective knockdown levels due to its high transfection efficiency.
The X-tremeGENE siRNA Transfection Reagent is intended for research applications only.
For the most current list of successfully transfected cell types, visit www.powerful-transfection.com.
- The X-tremeGENE siRNA Transfection Reagent delivers all the benefits of high transfection efficiency, low cytotoxicity, and the capability of transfecting a broad range of cell types.
- Perform effective gene knockdown: Transfect with high efficiency to study the cellular and functional consequences of gene silencing – achieve over 90% gene knockdown in many different cell types.
- Maximize flexibility: Use a single reagent for siRNA- and co-transfection-based gene-knockdown experiments.
- Generate meaningful results: Employ a reagent with minimal cellular cytotoxicity to ensure that observed cellular effects are due to the transfected siRNA and not the transfection procedure.
- Benefit from an easy-to-use reagent: Effectively silence genes in just two easy steps, increase your productivity, and extend your resources.
Androgen Receptor Controls EGFR and ERBB2 Gene Expression at Different Levels in Prostate Cancer Cell Lines
Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in men in developed countries. At diagnosis most prostate cancers are androgen dependent, meaning their growth, survival and progression are driven by the androgen-activated androgen receptor. This application note describes a study on androgenic regulation of EGFR and ERBB2 expression in prostate cancer cell lines presenting different androgen sensitivities. Inhibition of local androgen production could be an efficient way to stop the progression of prostate cancer, similar to treatment of breast cancers using aromatase inhibitors.
